1. Pershing Square Capital Management sold its entire stake in Valeant Pharmaceutical Industries. That firm lost about $4 billion in two years as a result of its stake in the drugmaker. (NYT)
2. Novartis received FDA approval to market a combination of its experimental drug kisqali and letrozole to treat breast cancer in postmenopausal women as a first-line treatment. More than half of patients achieved progression-free survival in a late-stage trial. (Reuters)
3. Express Scripts asked Gilead Sciences to offer a lower price for its hepatitis-C drugs Sovaldi and Harvoni, in response to recent comments made by a Gilead executive who said PBMs are the ones to blame for high drug prices. An Express Scripts executive responded, asking Gilead CEO John Milligan for discounted prices. (Healio)
4. In 10 years, an estimated 24 million people will not have health insurance as a result of the new President Trump-backed healthcare plan, according to an analysis by the Congressional Budget Office. His legislation would reduce the deficit by $337 billion in the same period. (WaPo)
5. Allergan’s R&D deal with Editas Medicine would give it exclusive access to gene-editing-based eye treatments developed by Editas’ CRISPR gene-editing technology. The deal would allow Allergen to license five of Editas’ gene-editing-based eye treatments. (Reuters)
